Don't miss

Replay


LATEST SHOWS

FOCUS

Ghana votes in tight presidential race

Read more

ENCORE!

Film show: 'Graduation', 'Go Home' & Hollywood legend Kirk Douglas turns 100

Read more

IN THE PAPERS

French educational system 'as mediocre as always'

Read more

IN THE PAPERS

Southern India bids farewell to 'Amma'

Read more

FACE-OFF

2017 French presidential election: Can Valls unite the left?

Read more

BUSINESS DAILY

Trump wins $50bn US investment from Japan's Softbank

Read more

THE DEBATE

France 24 turns ten: How to cover a changing world (part 1)

Read more

MEDIAWATCH

Interior minister takes over as France's premier

Read more

EYE ON AFRICA

Former LRA commander Ongwen pleads not guilty to 70 counts of war crimes

Read more

Two thirds of people with AIDS lack access to drugs

Latest update : 2008-06-02

Three million people suffering from AIDS have access to treatment thanks in part to the growing availability of cheap generic drugs, says the WHO, though they still only represent about a third of all AIDS victims in developing countries.

LONDON - Nearly 3 million people in the developing world now get AIDS drugs -- 1 million more than a year ago -- but two-thirds of those in need still lack access to treatment, the World Health Organisation said on Monday.

 

The increase in use reflects deep cuts in the price of branded medicines and widespread availability of cheap generics. The total represents 31 percent of the 9.7 million people living with HIV in low- and middle-income countries who need the reatment, officials said. Most live in sub-Saharan Africa.

 

"The answer to the HIV epidemic is preventing new infections," said WHO HIV/AIDS Director Kevin De Cock. "An additional 1 million people came on to therapy but another 2.5 million became newly infected with HIV, so we have to do better with prevention."

 

The WHO report estimated that meeting universal prevention and treatment targets means funding would have to quadruple to $35 billion in 2010 and $41 billion in 2015.

 

The AIDS virus infects an estimated 33 million people globally, mostly in poor, sub-Saharan Africa, and has killed 25 million.

 

There is no cure or vaccine but antiretroviral therapy -- suppressing replication of HIV by interfering with its genetic workings -- can keep people healthy for years even if they never eradicate the virus. This means people must take them for life.

 

Leading manufacturers of AIDS drugs include GlaxoSmithKline , Gilead, Roche, Pfizer, Merck Inc, Bristol-Myers Squibb and Abbott Laboratories.

 

The WHO also reported progress in preventing HIV in children with nearly 500,000 women receiving AIDS drugs to prevent transmission to their unborn children.

 

This was up from 350,000 in 2006, although diagnosing HIV in infants remains a major hurdle, the WHO said. During the same time period, 200,00 children got antiretroviral drugs, up from 127,000 a year earlier.

 

"There is a long way to go but it is a substantial increase," De Cock said in a telephone interview.

 

While price cuts have helped make the life-saving drugs more widely available, crumbling health systems in poor countries pose a major challenge, De Cock added.

 

In particular, difficulties in training and retaining health care workers due to a "brain drain" of the most skilled personnel to richer countries will slow future delivery of drugs, the WHO said.

 

"Obstacles include weak health care systems, a critical shortage of human resources and a lack of sustainable, long-term funding," the WHO report said.  

Date created : 2008-06-02

COMMENT(S)